Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial

Take the risk of cardiovascular side effects into account when prescribing tiotropium delivered via Respimat or Handihaler to patients with certain cardiac conditions, who were excluded from clinical trials of tiotropium (including TIOSPIR).